Report cover image

Global Angiogenesis Modulators Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 101 Pages
SKU # APRC20548738

Description

Summary

According to APO Research, The global Angiogenesis Modulators market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Angiogenesis Modulators is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Angiogenesis Modulators is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Angiogenesis Modulators is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Angiogenesis Modulators include Bayer Pharma AG (Germany), Bionomics Ltd. (Australia), CASI Pharmaceuticals, Inc. (USA), Celgene Corporation (USA), F.Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (USA), AstraZeneca plc (UK), Amgen, Inc. (USA) and GlaxoSmithKline plc (UK), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Angiogenesis Modulators, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiogenesis Modulators.
The Angiogenesis Modulators market size, estimations, and forecasts are provided in terms of sales volume (k tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Angiogenesis Modulators market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Angiogenesis Modulators Segment by Company

Bayer Pharma AG (Germany)
Bionomics Ltd. (Australia)
CASI Pharmaceuticals, Inc. (USA)
Celgene Corporation (USA)
F.Hoffmann-La Roche AG (Switzerland)
Genentech, Inc. (USA)
AstraZeneca plc (UK)
Amgen, Inc. (USA)
GlaxoSmithKline plc (UK)
Eli Lilly and Company (USA)
Eisai (Japan)
Angiogenesis Modulators Segment by Type

Angiogenesis Stimulators
Angiogenin
Angiogenesis Inhibitors
Others
Angiogenesis Modulators Segment by Application

Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Others
Angiogenesis Modulators Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiogenesis Modulators market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angiogenesis Modulators and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiogenesis Modulators.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Angiogenesis Modulators manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Angiogenesis Modulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

101 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Angiogenesis Modulators Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Angiogenesis Modulators Sales Estimates and Forecasts (2020-2031)
1.3 Angiogenesis Modulators Market by Type
1.3.1 Angiogenesis Stimulators
1.3.2 Angiogenin
1.3.3 Angiogenesis Inhibitors
1.3.4 Others
1.4 Global Angiogenesis Modulators Market Size by Type
1.4.1 Global Angiogenesis Modulators Market Size Overview by Type (2020-2031)
1.4.2 Global Angiogenesis Modulators Historic Market Size Review by Type (2020-2025)
1.4.3 Global Angiogenesis Modulators Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Angiogenesis Modulators Sales Breakdown by Type (2020-2025)
1.5.2 Europe Angiogenesis Modulators Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Angiogenesis Modulators Sales Breakdown by Type (2020-2025)
1.5.4 South America Angiogenesis Modulators Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Angiogenesis Modulators Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Angiogenesis Modulators Industry Trends
2.2 Angiogenesis Modulators Industry Drivers
2.3 Angiogenesis Modulators Industry Opportunities and Challenges
2.4 Angiogenesis Modulators Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Angiogenesis Modulators Revenue (2020-2025)
3.2 Global Top Players by Angiogenesis Modulators Sales (2020-2025)
3.3 Global Top Players by Angiogenesis Modulators Price (2020-2025)
3.4 Global Angiogenesis Modulators Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Angiogenesis Modulators Major Company Production Sites & Headquarters
3.6 Global Angiogenesis Modulators Company, Product Type & Application
3.7 Global Angiogenesis Modulators Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Angiogenesis Modulators Market CR5 and HHI
3.8.2 Global Top 5 and 10 Angiogenesis Modulators Players Market Share by Revenue in 2024
3.8.3 2023 Angiogenesis Modulators Tier 1, Tier 2, and Tier 3
4 Angiogenesis Modulators Regional Status and Outlook
4.1 Global Angiogenesis Modulators Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Angiogenesis Modulators Historic Market Size by Region
4.2.1 Global Angiogenesis Modulators Sales in Volume by Region (2020-2025)
4.2.2 Global Angiogenesis Modulators Sales in Value by Region (2020-2025)
4.2.3 Global Angiogenesis Modulators Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Angiogenesis Modulators Forecasted Market Size by Region
4.3.1 Global Angiogenesis Modulators Sales in Volume by Region (2026-2031)
4.3.2 Global Angiogenesis Modulators Sales in Value by Region (2026-2031)
4.3.3 Global Angiogenesis Modulators Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Angiogenesis Modulators by Application
5.1 Angiogenesis Modulators Market by Application
5.1.1 Breast Cancer
5.1.2 Prostate Cancer
5.1.3 Colorectal Cancer
5.1.4 Lung Cancer
5.1.5 Others
5.2 Global Angiogenesis Modulators Market Size by Application
5.2.1 Global Angiogenesis Modulators Market Size Overview by Application (2020-2031)
5.2.2 Global Angiogenesis Modulators Historic Market Size Review by Application (2020-2025)
5.2.3 Global Angiogenesis Modulators Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Angiogenesis Modulators Sales Breakdown by Application (2020-2025)
5.3.2 Europe Angiogenesis Modulators Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Angiogenesis Modulators Sales Breakdown by Application (2020-2025)
5.3.4 South America Angiogenesis Modulators Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Angiogenesis Modulators Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Bayer Pharma AG (Germany)
6.1.1 Bayer Pharma AG (Germany) Comapny Information
6.1.2 Bayer Pharma AG (Germany) Business Overview
6.1.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bayer Pharma AG (Germany) Angiogenesis Modulators Product Portfolio
6.1.5 Bayer Pharma AG (Germany) Recent Developments
6.2 Bionomics Ltd. (Australia)
6.2.1 Bionomics Ltd. (Australia) Comapny Information
6.2.2 Bionomics Ltd. (Australia) Business Overview
6.2.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bionomics Ltd. (Australia) Angiogenesis Modulators Product Portfolio
6.2.5 Bionomics Ltd. (Australia) Recent Developments
6.3 CASI Pharmaceuticals, Inc. (USA)
6.3.1 CASI Pharmaceuticals, Inc. (USA) Comapny Information
6.3.2 CASI Pharmaceuticals, Inc. (USA) Business Overview
6.3.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.3.4 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Product Portfolio
6.3.5 CASI Pharmaceuticals, Inc. (USA) Recent Developments
6.4 Celgene Corporation (USA)
6.4.1 Celgene Corporation (USA) Comapny Information
6.4.2 Celgene Corporation (USA) Business Overview
6.4.3 Celgene Corporation (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Celgene Corporation (USA) Angiogenesis Modulators Product Portfolio
6.4.5 Celgene Corporation (USA) Recent Developments
6.5 F.Hoffmann-La Roche AG (Switzerland)
6.5.1 F.Hoffmann-La Roche AG (Switzerland) Comapny Information
6.5.2 F.Hoffmann-La Roche AG (Switzerland) Business Overview
6.5.3 F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.5.4 F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Product Portfolio
6.5.5 F.Hoffmann-La Roche AG (Switzerland) Recent Developments
6.6 Genentech, Inc. (USA)
6.6.1 Genentech, Inc. (USA) Comapny Information
6.6.2 Genentech, Inc. (USA) Business Overview
6.6.3 Genentech, Inc. (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Genentech, Inc. (USA) Angiogenesis Modulators Product Portfolio
6.6.5 Genentech, Inc. (USA) Recent Developments
6.7 AstraZeneca plc (UK)
6.7.1 AstraZeneca plc (UK) Comapny Information
6.7.2 AstraZeneca plc (UK) Business Overview
6.7.3 AstraZeneca plc (UK) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.7.4 AstraZeneca plc (UK) Angiogenesis Modulators Product Portfolio
6.7.5 AstraZeneca plc (UK) Recent Developments
6.8 Amgen, Inc. (USA)
6.8.1 Amgen, Inc. (USA) Comapny Information
6.8.2 Amgen, Inc. (USA) Business Overview
6.8.3 Amgen, Inc. (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Amgen, Inc. (USA) Angiogenesis Modulators Product Portfolio
6.8.5 Amgen, Inc. (USA) Recent Developments
6.9 GlaxoSmithKline plc (UK)
6.9.1 GlaxoSmithKline plc (UK) Comapny Information
6.9.2 GlaxoSmithKline plc (UK) Business Overview
6.9.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.9.4 GlaxoSmithKline plc (UK) Angiogenesis Modulators Product Portfolio
6.9.5 GlaxoSmithKline plc (UK) Recent Developments
6.10 Eli Lilly and Company (USA)
6.10.1 Eli Lilly and Company (USA) Comapny Information
6.10.2 Eli Lilly and Company (USA) Business Overview
6.10.3 Eli Lilly and Company (USA) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Eli Lilly and Company (USA) Angiogenesis Modulators Product Portfolio
6.10.5 Eli Lilly and Company (USA) Recent Developments
6.11 Eisai (Japan)
6.11.1 Eisai (Japan) Comapny Information
6.11.2 Eisai (Japan) Business Overview
6.11.3 Eisai (Japan) Angiogenesis Modulators Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Eisai (Japan) Angiogenesis Modulators Product Portfolio
6.11.5 Eisai (Japan) Recent Developments
7 North America by Country
7.1 North America Angiogenesis Modulators Sales by Country
7.1.1 North America Angiogenesis Modulators Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Angiogenesis Modulators Sales by Country (2020-2025)
7.1.3 North America Angiogenesis Modulators Sales Forecast by Country (2026-2031)
7.2 North America Angiogenesis Modulators Market Size by Country
7.2.1 North America Angiogenesis Modulators Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Angiogenesis Modulators Market Size by Country (2020-2025)
7.2.3 North America Angiogenesis Modulators Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Angiogenesis Modulators Sales by Country
8.1.1 Europe Angiogenesis Modulators Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Angiogenesis Modulators Sales by Country (2020-2025)
8.1.3 Europe Angiogenesis Modulators Sales Forecast by Country (2026-2031)
8.2 Europe Angiogenesis Modulators Market Size by Country
8.2.1 Europe Angiogenesis Modulators Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Angiogenesis Modulators Market Size by Country (2020-2025)
8.2.3 Europe Angiogenesis Modulators Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Angiogenesis Modulators Sales by Country
9.1.1 Asia-Pacific Angiogenesis Modulators Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Angiogenesis Modulators Sales by Country (2020-2025)
9.1.3 Asia-Pacific Angiogenesis Modulators Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Angiogenesis Modulators Market Size by Country
9.2.1 Asia-Pacific Angiogenesis Modulators Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Angiogenesis Modulators Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Angiogenesis Modulators Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Angiogenesis Modulators Sales by Country
10.1.1 South America Angiogenesis Modulators Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Angiogenesis Modulators Sales by Country (2020-2025)
10.1.3 South America Angiogenesis Modulators Sales Forecast by Country (2026-2031)
10.2 South America Angiogenesis Modulators Market Size by Country
10.2.1 South America Angiogenesis Modulators Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Angiogenesis Modulators Market Size by Country (2020-2025)
10.2.3 South America Angiogenesis Modulators Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Angiogenesis Modulators Sales by Country
11.1.1 Middle East and Africa Angiogenesis Modulators Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Angiogenesis Modulators Sales by Country (2020-2025)
11.1.3 Middle East and Africa Angiogenesis Modulators Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Angiogenesis Modulators Market Size by Country
11.2.1 Middle East and Africa Angiogenesis Modulators Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Angiogenesis Modulators Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Angiogenesis Modulators Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Angiogenesis Modulators Value Chain Analysis
12.1.1 Angiogenesis Modulators Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Angiogenesis Modulators Production Mode & Process
12.2 Angiogenesis Modulators Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Angiogenesis Modulators Distributors
12.2.3 Angiogenesis Modulators Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.